Table 3.
Two or more QT-prolonging drug–drug interactions according to CredibleMeds® risk category and mechanism
| QT-DDIs | n (N = 15) | List 1a | List 2a | List 3a | QT-DDI classification |
|---|---|---|---|---|---|
| Citalopram–omeprazole | 4 | 1 | 0 | 1 | PK |
| Citalopram–pantoprazole | 3 | 1 | 0 | 1 | PK |
| Quetiapine–trazodone | 2 | 0 | 0 | 2 | PD |
| Citalopram–clarithromycin | 2 | 2 | 0 | 0 | PD |
| Clarithromycin–amiodarone | 2 | 2 | 0 | 0 | PK, PD |
| Clarithromycin–paroxetine | 2 | 1 | 0 | 1 | PD |
DDI drug–drug interaction, PD pharmacodynamics, PK pharmacokinetics, QT-DDIs DDIs with a potential risk of QT interval prolongation identified using the IBM Micromedex Drugdex® drug interactions tool
aClassification from https://www.crediblemeds.org. List 1 = drugs with known risk of torsade de pointes; list 2 = drugs with possible risk of torsade de pointes; list 3 = drugs with conditional risk of torsade de pointes